Iterum on deck for IPO of upto $92 M

May 3, 2018 | Thursday | News

The clinical-stage pharma company is focused on developing an antibiotic called sulopenem that it licensed from Pfizer in late 2015.

Singapore- Dublin, Ireland-domiciled Iterum Therapeutics (ITRM) has filed a preliminary prospectus for its U.S. IPO.

The clinical-stage pharma company is focused on developing an antibiotic called sulopenem that it licensed from Pfizer in late 2015. The company says there are two main opportunities for the ß-lactam antibiotic: patients in a community setting with uncomplicated urinary tract infections at elevated risk of treatment failure and hospitalized patients with complicated antibiotic-resistant infections.

Sign up for the editor pick and get articles like this delivered right to your inbox.

+Country Code-Phone Number(xxx-xxxxxxx)

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

Survey Box

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls